2000PubMedRequires access

[Prophylactic treatment of migraine].

C. Le Jeunne

Open publisher page 1 citations

Abstract

Because of the outcome of the 5 HT1B/1D agonists or "triptans" for the treatment of migraine attacks, it has been thought that migraine prophylaxis was not useful anymore. However, some patients are not responders to the triptans and some responders who have more than one attack a week still feel the need for prophylactic treatment. Apart from non-pharmacological treatments that are always needed, the different drugs that have shown their efficiency in clinical trials are analysed. The choice of a prophylactic treatment mostly depends on the benefits/risk ratio. In migraine prophylaxis beta-blockers have a good benefits/risk ratio, serotonin receptor antagonists that are effective as well, have a high frequency of adverse effects, especially weight gain and fatigue, which are limiting factors for prescription. In France dihydroergotamine is still largely prescribed because it is well tolerated. Second-line treatments may be considered, they have been studied through clinical trials, they are efficient, but they have severe side effects: flunarizine, sodium valproate and methysergide. The management of all these side effects has to be known, because prophylactic treatment is still necessary for the well-being of migraineurs.

About this research paper

What this paper is about

Because of the outcome of the 5 HT1B/1D agonists or "triptans" for the treatment of migraine attacks, it has been thought that migraine prophylaxis was not useful anymore. However, some patients are not responders to the triptans and some responders who have more than one attack a week still feel the need for prophylactic treatment. Apart from non-pharmacological treatments that are always needed, the different drugs that have shown their efficiency in clinical trials are analysed. The choice of a prophylactic treatment mostly depends on the benefits/risk ratio. In migraine prophylaxis beta-blockers have a good benefits/risk ratio, serotonin receptor antagonists that are effective as well, have a high frequency of adverse effects, especially weight gain and fatigue, which are limiting factors for prescription. In France dihydroergotamine is still largely prescribed because it is well tolerated. Second-line treatments may be considered, they have been studied through clinical trials, they are efficient, but they have severe side effects: flunarizine, sodium valproate and methysergide. The management of all these side effects has to be known, because prophylactic treatment is still necessary for the well-being of migraineurs.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Because of the outcome of the 5 HT1B/1D agonists or "triptans" for the treatment of migraine attacks, it has been thought that migraine prophylaxis was not useful anymore. However, some patients are not responders to the triptans and some responders who have more than one attack a week still feel the need for prophylactic treatment. Apart from non-pharmacological treatments that are always needed, the different drugs that have shown their efficiency in clinical trials are analysed. The choice of a prophylactic treatment mostly depends on the benefits/risk ratio. In migraine prophylaxis beta-blockers have a good benefits/risk ratio, serotonin receptor antagonists that are effective as well, have a high frequency of adverse effects, especially weight gain and fatigue, which are limiting factors for prescription. In France dihydroergotamine is still largely prescribed because it is well tolerated. Second-line treatments may be considered, they have been studied through clinical trials, they are efficient, but they have severe side effects: flunarizine, sodium valproate and methysergide. The management of all these side effects has to be known, because prophylactic treatment is still necessary for the well-being of migraineurs.

Key concepts: Triptans, Dihydroergotamine, Medicine, Migraine, Methysergide, Prophylactic treatment, Flunarizine, Migraine treatment

Related papers

Back to paper searchBrowse research topicsOriginal source
[Prophylactic treatment of migraine]. — Research Paper | ScholarLens